Trial reportCMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne2012
The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial.
Trial report in CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2012. The graph read 2 numbers from its abstract, feeding 2 cells of the map: it supports the treatment in 1, finds no clear difference in 1. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
In analyses restricted to events occurring before a cardiovascular event, pneumonia occurred in 203 participants given rosuvastatin and 250 given placebo (HR 0.81, 95% CI 0.67-0.97).
RESULTS: Among 17,802 trial participants followed for a median of 1.9 years, incident pneumonia was reported as an adverse event in 214 participants in the rosuvastatin group and 257 in the placebo group (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.69-1.00).
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Statins×cardiovascular events
SupportsOpen on the map →What to test next →30 readable studies in this cell: 18 favour the treatment, 11 find no difference, 1 favour the comparator.
Statins×adverse events & safety
InconclusiveOpen on the map →What to test next →11 readable studies in this cell: 3 favour the treatment, 7 find no difference, 1 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 89 citations in OpenAlex.
- Unintended effects of statins from observational studies in the general population: systematic review and meta-analysis.BMC medicine · 2014 · on this mapPooled it
- Preliminary results of pravastatin on non-hemorrhagic vertebral artery dissection: an exploratory randomized and controlled study.BMC neurology · 2025Trial
- PCSK9 is a critical regulator of the innate immune response and septic shock outcome.Science translational medicine · 2014Trial
- Biomarkers and bacterial pneumonia risk in patients with treated HIV infection: a case-control study.PloS one · 2013Trial
- Dyslipidemia in Diabetes: Navigating a Complex Landscape for Improved Cardiovascular Outcomes.Clinical medicine insights. Endocrinology and diabetes · 2026Review
- Beyond LDL Cholesterol Reduction: Pleiotropic Profiling of Statins.Current atherosclerosis reports · 2025Review
- Impact of Long-Term Statin Therapy on Incidence and Severity of Community-Acquired Pneumonia: A Real-World Data Analysis.Biomedicines · 2025Article
- The Association Between Statin Therapy and the Subsequent Clinical Course of Patients With Melioidosis.Journal of tropical medicine · 2025Article
- Statin Use and Reduced Risk of Pneumonia in Patients with Melioidosis: A Lung-Specific Statin Association.Annals of the American Thoracic Society · 2024Article
- Statins Show Promise Against Progression of Liver Disease.Clinical liver disease · 2021Review
- SARS-CoV-2 and Pre-existing Vascular Diseases: Guilt by Association?Clinical Medicine Insights. Cardiology · 2021Review
- Article
- Statins and COVID-19: To Suspend or Not to Suspend? That is the Question!Arquivos brasileiros de cardiologia · 2021Article
- Statins and PCSK9 inhibitors: What is their role in coronavirus disease 2019?Medical hypotheses · 2021Review
- Statins: Could an old friend help in the fight against COVID-19?British journal of pharmacology · 2020Review
- Cardiovascular manifestation and treatment in COVID-19.Journal of the Chinese Medical Association : JCMA · 2020Review
- COVID-19 for the Cardiologist: Basic Virology, Epidemiology, Cardiac Manifestations, and Potential Therapeutic Strategies.JACC. Basic to translational science · 2020Review
- Effect of Statins on the Risk of Poststroke Pneumonia: National Population-Based Cohort Study.Infection and drug resistance · 2020Article
- Association between Tuberculosis, Statin Use, and Diabetes: A Propensity Score-Matched Analysis.The American journal of tropical medicine and hygiene · 2019Article
- Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol.Lipids in health and disease · 2019Review
Corrections and comments
- Commented on by
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
backgroundEvidence from observational studies have raised the possibility that statin treatment reduces the incidence of certain bacterial infections, particularly pneumonia. We analyzed data from a randomized controlled trial of rosuvastatin to examine this hypothesis.
methodsWe analyzed data from the randomized, double-blind, placebo-controlled JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin). In this trial, 17,802 healthy participants (men 50 years and older and women 60 and older) with a low-density lipoprotein (LDL) cholesterol level below 130 mg/dL (3.4 mmol/L) and a high-sensitivity C-reactive protein level of 2.0 mg/L or greater were randomly assigned to receive either rosuvastatin or placebo. We evaluated the incidence of pneumonia on an intention-to-treat basis by reviewing reports of adverse events from the study investigators, who were unaware of the treatment assignments.
resultsAmong 17,802 trial participants followed for a median of 1.9 years, incident pneumonia was reported as an adverse event in 214 participants in the rosuvastatin group and 257 in the placebo group (hazard ratio [HR] 0.83, 95% confidence interval [CI] 0.69-1.00). In analyses restricted to events occurring before a cardiovascular event, pneumonia occurred in 203 participants given rosuvastatin and 250 given placebo (HR 0.81, 95% CI 0.67-0.97). Inclusion of recurrent pneumonia events did not modify this effect (HR 0.81, 95% CI 0.67-0.98), nor did adjustment for age, sex, smoking, metabolic syndrome, lipid levels and C-reactive protein level.
interpretationData from this randomized controlled trial support the hypothesis that statin treatment may modestly reduce the incidence of pneumonia. (ClinicalTrials.gov trial register no. NCT0023968.).
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.